期刊
ANTIVIRAL RESEARCH
卷 66, 期 2-3, 页码 99-102出版社
ELSEVIER SCIENCE BV
DOI: 10.1016/j.antiviral.2005.01.002
关键词
interferon; alfacon 1; SARS-corona; antiviral; therapy
Preliminary data examining interferon alfacon 1 treatment of SARS-CoV (severe acute respiratory syndrome-corona virus)-infected patients suggests this therapy is well tolerated and of therapeutic benefit. We report herein that interferon alfacon 1, has potent in vitro antiviral activity against SARS-CoV. In a cytopathic effect protection (CPE) assay, interferon alfacon I inhibited the generation of CPE in a dose-dependent manner with an IC50 of 0.001 mu g/ml, a clinically achievable level. Furthermore, interferon alfacon 1 also demonstrated significant antiviral activity in yield reduction and plaque reduction assays. The in vitro antiviral activity of interferon alfacon 1 against SARS-CoV suggests continued evaluation of interferon alfacon 1 as a therapeutic treatment for patients infected with SARS-CoV. Published by Elsevier B.V.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据